Dako enters into collaboration with Genentech on the FDA regulatory submissions of Dako's HercepTest(TM) and HER2 FISH pharmDx(TM) as companion diagnostics for trastuzumab emtansine (T-DM1)
(Thomson Reuters ONE) -
Dako, a worldwide provider of cancer diagnostics solutions, has signed an
agreement with Genentech, member of the Roche Group, to collaborate on the
regulatory submissions of Dako's HercepTest(TM) and HER2 FISH pharmDx(TM) as
companion diagnostics for a Genentech investigational drug candidate,
trastuzumab emtansine (T-DM1), in patients with advanced HER2-positive breast
cancer.
Under the terms of the agreement, Dako and Genentech will collaborate on the
regulatory FDA submissions of HercepTest(TM) and HER2 FISH pharmDx(TM) to
identify cancer patients who may be eligible for treatment with trastuzumab
emtansine.
"It is a pleasure to welcome Genentech as a partner once again. Working with
Genentech on this FDA submission for companion diagnostics for trastuzumab
emtansine is another important step forward in our relentless commitment to
fighting cancer," says Lars Holmkvist, CEO of Dako.
The collaboration on the submission process for HercepTest(TM) and HER2 FISH
pharmDx(TM) as companion diagnostics for trastuzumab emtansine is in line with
Dako's ongoing strategy to combine its strengths with pharmaceutical companies
to grow the offering of Dako's companion diagnostic assays.
"At Dako we are constantly looking for new opportunities to move pathology
forward, and we see this new agreement as a sign of confidence in Dako's leading
competencies within the area of companion diagnostics," says Lars Holmkvist.
Today's announcement comes on the heels of a recently announced collaboration
between Dako and Genentech on the regulatory submissions of Dako's
HercepTest(TM) and HER2 FISH pharmDx(TM) as companion diagnostics for another
Genentech investigational drug candidate - Pertuzumab.
Media contact
Maia Fredtoft Søchting
Corporate Communications
Dako Denmark A/S
Tel. +45 25 46 10 83
About Dako
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's know-how, reagents,
instruments and software to make accurate diagnoses and determine the most
effective treatment for patients suffering from cancer. Employing more than
1,000 people and being present in more than 80 countries, Dako covers
essentially all of the anatomic pathology markets globally. Dako is owned by
private equity fund EQT V. www.dako.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
[HUG#1607661]
Unternehmensinformation / Kurzprofil:
Datum: 01.05.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 141171
Anzahl Zeichen: 3149
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dako enters into collaboration with Genentech on the FDA regulatory submissions of Dako's HercepTest(TM) and HER2 FISH pharmDx(TM) as companion diagnostics for trastuzumab emtansine (T-DM1)"
steht unter der journalistisch-redaktionellen Verantwortung von
Dako Denmark A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
